TOVX Theriva Biologics
- 0.4195
- +0.0096+2.33%
- 0.4077
- -0.0118-2.81%
Theriva Biologics News
Theriva Biologics To Discuss The Trial Design For VIRAGE - A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting
Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on th
Express News | Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of Hibbett, Inc. (NASDAQ:HIBB) rose sharply in today's pre-market trading after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transactio
Theriva Biologics' VCN-01 Shows Promise in Pediatric Cancer Trial
Express News | Theriva Biologics Inc - Intravitreal Vcn-01 Demonstrated Promising Antitumor Activity and Did Not Appear to Change Retinal Function
Express News | Theriva Biologics Inc - Vcn-01 Was Well Tolerated After Intravitreal Administration at 2 Doses
Express News | Theriva Biologics Inc - Data for 9 Evaluable Patients Were Reviewed by Study Monitoring Committee Who Agreed That Trial Had a Positive Outcome
Express News | Theriva™ Biologics Announces Positive Topline Data From Investigator Sponsored Phase 1 Trial of Intravitreal Vcn-01 in Pediatric Patients With Refractory Retinoblastoma
Express News | Theriva Biologics Shares Are Trading Higher After the Company Announced It Will Present Preclinical Data for the Potential Synergy of VCN-01 and First-line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annu
Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy
Express News | Theriva Biologics To Present Preclinical Data For Potential Synergy Of VCN-01 And First-Line Pancreatic Cancer Chemotherapy Regimens At American Society For Cell And Gene Therapy 27th Annual Meeting
Theriva Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Theriva Biologics (NYSE American: TOVX) today announced the presentation of preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate VCN-01 and liposomal irinotecan.
Theriva Biologics Upcoming Investor Presentations Insight
Buy Recommendation for Theriva Biologics Backed by Promising Oncolytic Adenovirus Platform and Clinical Trial Advancements
Q4 2023 Theriva Biologics Inc Earnings Call
Earnings Call Summary | Theriva Biologics(TOVX.US) Q4 2023 Earnings Conference
The following is a summary of the Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript:Financial Performance:Theriva Biologics reported a decrease in general and administrative expenses fro
Theriva Biologics GAAP EPS of -$1.14 Beats by $0.23
Express News | Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Press Release: Theriva(TM) Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
Theriva(TM) Biologics Reports Full-Year 2023 Operational Highlights and Financial Results -- The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clin
Earnings Scheduled For March 25, 2024
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million. • Syra Health (NASDAQ:SYRA) is likely to report
Analysis
Price Target
No Data
